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Background
Tumors of children reproductive system are rare, the most frequent among them is ovarian tumor. The most frequent histo­
logical type of ovarian tumor in girls and adolescents is germ cell tumor, with dysgerminoma being the most frequent of all. 
Symptoms are very non­specific, this is why these tumors are often diagnosed late. Dysgerminoma is a malignant tumor, thus 
if not treated, it may be potentially lethal.
Case report
We present a 16­year old patient, who has come to Vilnius University Hospital Santaros Klinikos, Children’s unit, due to a sud­
den emergence of a growth above the left clavicle. The girl did not have any other specific complaints. Huge hard growth was 
founded during palpation of the abdomen. After the cancer marker test (alfa­fetoprotein – 1,9 kU/L, beta­human chorionic 
gonadotropin – 1231.0 U/L; lactate dehydrogenase – 2721.0 U/L; Ca125 – 665.8 kU/L), pelvic ultrasound examination, com­
puted tomography and histological evaluation of the supraclavicular mass, dysgerminoma of the right ovary FIGO stage IV 
was diagnosed. The patient was treated with laparotomic oophorectomy and chemotherapy before and after surgery. Treat­
ment was successful as 100% of tumor cells necrosis was achieved.
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Conclusions
Girls and adolescents should be suspect to ovarian masses if they complains about abdominal pain, a growth in the abdomi­
nal area, disruptions of menstrual cycle or signs of premature puberty. Early diagnosis and treatment of ovarian dysgermi­
noma have a very good recovery rate in girls and adolescent.
Key words: ovarian tumors in girls and adolescents, malignant germ cell tumors, dysgerminoma, nonepithelial tumors.
Įvadas
Vaikų reprodukcinės sistemos navikai yra reti, būdingiausias iš jų – kiaušidžių navikas. Germinogeniniai navikai – dominuo­
jantis mergaičių, ypač paauglių, kiaušidžių navikų histologinis tipas. Iš šių navikų dažniausia disgerminoma. Simptomai labai 
nespecifiniai, todėl navikai diagnozuojami vėlai. Disgerminoma – piktybinis navikas, todėl negydant prognozė gali būti letali. 
Atvejo aprašymas
Į Vilniaus universiteto ligoninės Santaros klinikų Vaikų ligoninės priėmimo skyrių kreipėsi 16 m. pacientė dėl kairėje viršrak­
tikaulinėje srityje staiga atsiradusio darinio. Kitų specifinių skundų mergina neturėjo. Čiuopiant pilvą aptiktas didelis kietas 
darinys. Atlikus vėžio žymenų tyrimus (alfa fetoproteinas – 1,9 kU/L, beta chorioninis gonadotropinas – 1231,0 U/L; lakatato 
dehidrogenazė – 2721,0 U/L; Ca125 – 665,8 kU/L), dubens organų ultragarsą, kompiuterinę tomografiją ir viršraktikaulinio 
darinio histologinį tyrimą, pacientei diagnozuota FIGO IV stadijos dešinės kiaušidės disgerminoma. Pacientei prieš operacinį 
gydymą ir po jo buvo atlikta laparatominė ovarektomija ir chemoterapija. Gydymas buvo sėkmingas – rasta 100 proc. naviko 
ląstelių nekrozė.
Išvados
Mergaitėms, ypač paauglėms,  gali būti įtartas kiaušidžių darinys, jei skundžiamasi pilvo skausmu, dariniu pilve, nereguliariu 
mėnesinių ciklu ar ankstyva branda. Ankstyva mergaičių, ypač paauglių, disgerminomų diagnostika ir gydymas lemia labai 
gerą šių navikų prognozę.
Reikšminiai žodžiai: mergaičių, ypač paauglių, kiaušidžių navikai, piktybiniai germinogeniniai navikai, disgerminoma, ne­
epiteliniai navikai.
Introduction
Tumors of children reproductive system are rare [1], 
the most frequent among them is ovarian tumor [2]. 
About half of all ovarian masses founded in juvenile 
and adolescent girls are neoplastic [1, 3, 4]. It accounts 
for 2.6/100 000 cases every year [5]. Approximately 
10–20% of all neoplastic masses are malignant [1–4, 
6–14]. Malignant ovarian tumors constitute 1–2 per-
cent of all children’s malignant tumor cases and  3% of 
girl’s malignant tumor cases [2, 4, 7–10, 12]. Unlike 
adult females, juvenile and adolescent girls often have 
tumors of non-epithelial origin [2], they comprise as 
much as 80% of all tumors [2, 8, 9]. The most frequent 
among them are germ cell ovarian tumors (60–80% of 
all non-epithelial ovarian tumors) [1, 2, 4, 8, 14]. Young 
girls with ovarian tumors generally have a better survival 
rate than older women [2]. The 5 year overall survival 
(OS) of patients with malignant tumors of all stages is 
98.5% (95% confidence interval (CI): 95.6–100%), 
5 year event free survival (EFS) is  84.5% (95% CI: 
76.5–93.5%) [16]. The survival of patients with early 
stages of malignant tumors after surgery and adjuvant 
chemotherapy (with platinum) is 90% [13]. The 5 year 
survival of patients with the first stage tumors is 95.6%, 
with advanced stage tumors – 73.2%, total survival rate 
(all tumors) is 89.4% [2].
Case report
16 year old patient arrived to Santaros Klinikos of 
Vilnius University Hospital, Children’s unit, with a 
sudden formation above the left clavicle. The girl com-
plained about frequent defecation (1–2 times daily), 
weight loss (9 kg per 2 months), dry cough (for about 
1 month), and general weakness (for about 2 weeks). 
The examination results were as follows: pale skin, 
visible and palpable, painless and immobile forma-
tion above the left clavicle (4x4 cm). The patient was 
coughing irritably, vesicular breathing pattern on both 
chest sides was heard during the auscultation, and 
there was no crepitation. There was a visible abdominal 
asymmetry, and a palpable, large (30x30x35 cm) and 
hard formation in the abdomen, slightly on the right 
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side. Laboratory test results showed: alfa-fetoprotein 
(AFP) – 1,9 kU/L, beta-human chorionic gonadotro-
pin (beta-hCG) – 1231.0 U/L; lactate dehydrogenase 
(LDH) – 2721.0 U/L; Ca125 – 665.8 kU/L. Liver and 
kidney function was normal, C reactive protein (CRP) 
was 54,6 mg/L. Pelvic ultrasound (US) examination 
showed a large (46x28x18 cm), solid, heterogeneous 
(with liquid spaces and calcinates) formation, growing 
out of the right ovary, and free fluid inside the abdomen. 
Computed tomography (CT) was used to verify the US 
examination findings, the results were as follows: supra-
clavicular pathological masses, pathological masses in 
the posterior mediastinum, bilateral pleurisy and fluid 
in the pleural space; pathological formation in the abdo-
men and pelvis: it’s size was 27.24x25.51x13.25 cm, the 
tumor was lobulated, consisting of two big nodes, it had 
necrotic zones and calcinates; hepatosplenomegaly; free 
fluid in the abdominal cavity. Germ cell ovarian tumor 
with metastases in the supraclavicular lymph nodes was 
suspected. Following a biopsy of the supraclavicular 
lymph nodes, the suspicion was confirmed. No metas-
tases were found in the bone marrow. The patient was 
diagnosed with dysgerminoma of the right ovary FIGO 
stage IV. The patient was prescribed chemotherapy treat-
ment – three cycles of BEP (cisplatin / etoposide / bleo-
mycin). Later beta-hCG, LDH and Ca125 decreased 
till 5.9 U/L, 418.0 U/L and 169.9 U/L, respectively. 
CT also was repeated after chemotherapy: there were 
no pathological masses left in the left supraclavicular 
area; the ovarian tumor and lymph nodes conglomerates 
in the posterior mediastinum and the retroperitoneal 
space showed a partial response to the treatment – 50% 
reduction; hepatosplenomegaly persists; pleural and 
abdominal cavity fluids were no longer present. The 
decision was made to operate the patient. During the 
laparotomy, the right ovary and the affected part of the 
right fallopian tube were removed. The hardened and 
enlarged para-aortic lymph nodes of the retroperitoneal 
space were removed as well. Results of the histological 
examination showed: dysgerminoma of the right ovary; 
metastases of dysgerminoma in the supraclavicular 
lymph nodes; full post-therapeutic regression of ovarian 
dysgerminoma and metastases in the supraclavicular 
lymph nodes: 100% post-therapeutic cell necrosis and 
fibrosis. An immunohistochemical examination showed 
that 100% of the tumor cells were positive for CD117 
and Salla4 markers. The 4th chemotherapy course was 
applied after the laparatomic oophorectomy. Then CT 
was repeated, and it showed active lymph nodes con-
glomerate, therefore it was decided to do relaparotomy. 
The para-aortic nodes of the retroperitoneal space were 
removed; histology showed necrotized cells of dysger-
minoma metastases. The patient’s five months duration 
treatment was successfully completed; long term follow-
up was applied to prevent potential relapse.
Discussion
In 2014 the World Health Organization (WHO) an-
nounced the new histological classification of ovarian 
tumors. In this classification, superficial epithelial ovar-
ian tumors are classified into serous, mucinous, endo-
metrioid, clear cell, Brenner, seromucinous, undifferen-
tiated, mezenchymal and mixed epithelial-mesenchymal 
tumors. Non epithelial tumors are divided into sex cord-
stromal and germ cell tumors. Among all histological 
types of tumors, benign, bordeline or malignant tumors 
are present [15]. Germ cell ovarian tumors are most 
commonly diagnosed in the first two decades of life, av-
eragely at 16–20 years [16]. They account for as much as 
70% of all ovarian tumors in women aged 10–30 years 
[1, 2, 4, 14]. 20–30% of germ cell tumors are malignant 
and represent 1–3% of all ovarian malignant tumors [4, 
16, 17]. Malignant germ cell tumors include immature 
teratomas, dysgerminomas, yolk sac tumors, embryonic 
tumors, choriocarcinomas, poliembriomas and mixed 
tumors. Other rare malignant germinal tumors belong 
to the heterogeneous tumor group [18, 19]. Immature 
teratomas, dysgerminomas, yolk sac tumors and mixed 
tumors account for 90% of all germ cell tumors (dys-
germinomas are the most common ones, 34% cases, 
immature teratomas make up 30% cases) [2, 16, 17]. 
Germ cell tumors are usually one-sided, discovered in 
the first stage and are susceptible to chemotherapy [2, 3, 
6, 7, 9], their prognosis is very good [1.9]. 5 year OS is 
>95%, the best survival rate is in case of dysgerminoma, 
the worst one is in case of immature teratomas, yolk sac 
tumors and mixed tumors [17].
Clinical diagnosis of ovarian tumors consists of clinic, 
cancer markers, US, CT/MRI (magnetic resonance 
imaging) and intraoperative data. The final diagnosis 
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of tumor is determined only after the findings of the 
histological examination [17–21]. Ovarian tumor is 
differentiated from the primary neoplastic and non-
neoplastic pathology of other organs (not ovaries). It 
should be kept in mind that ovaries may have secondary 
malignant tumors – i.e. metastases of tumors of other 
organs [18]. Ovarian tumors are usually asymptomatic 
in the early stages and are therefore diagnosed late. The 
most common symptom of ovarian tumors is abdominal 
pain. It can be accompanied by dyspepsia and disorders 
of urination or defecation. Menstrual disorders, signs of 
premature puberty or virilization are common. The tu-
mor can be discovered by performing a bimanual exami-
nation via the rectum, vagina or abdominal wall. Cancer 
markers typical for dysgerminomas are: AFP, beta-hCG, 
LDH, Ca125 [17–21]. Ovarian masses are diagnosed 
with transabdominal and transvaginal pelvic ultraso-
nography [17–21]. CT and / or MRI with contrast are 
used for differential diagnosis and appropriate staging 
[4, 17, 20]. Dysgerminomas are large, solid, lobulated, 
hyper / neo-vascularized tumors of varied echogenicity. 
Multiplicity, septations and compartments of the tumor 
are common [22, 23]. Tumor cells are positive for Salla4, 
OCT3/4 and CD117 markers during an immunohisto-
chemistry examination. In the future, these markers can 
be used for treatment with target therapy [18, 24, 25].
Gonadal dysgenesis is a risk factor for germ cell ovar-
ian tumors. Gonadoblastoma is a rare sex cord-stromal 
tumor. A pure gonadoblastoma is a benign tumor, but 
in 50–60% of cases it contains malignant germinal 
tumor cells [17], most frequently it is dysgerminoma 
[26, 27]. Gonadoblastoma is most often associated with 
gonadal dysgenesis [1]. Mutations of 12p chromosome 
and c-kit gene in 4q chromosome are found in >80% of 
dysgerminoma cases. It is thought that the mutation of 
kit gene leads to development of more malignant tumor. 
It has been observed that the amplification of kit gene is 
directly related to the expression of the KIT protein in 
tumor cells [28, 29].
Surgery and chemotherapy are used to treat malig-
nant ovarian tumors in girls and adolescents. The aim of 
the treatment is to leave as much of the healthy ovarian 
tissue as possible without compromising the radicallity 
of the treatment, since about 20% of cases are character-
ized by metachronous tumors in contralateral ovary [1, 
6–9]. Laparotomic oophorectomy is the first-line treat-
ment for the elimination of children’s malignant tumors 
[7, 21]. During the operation a partial surgical staging is 
performed. The stage of the tumor is established accord-
ing the FIGO classification [18, 19]. After the surgery 
adjuvant chemotherapy is prescribed to all patients 
except those with IA or IB dysgerminomas. First-line 
choice is 3/4 cycles of PEB (cisplatin / etoposide / bleo-
mycin). The neoadjuvant chemotherapy may also be 
applied, when tumor is inoperable. After the treatment 
the patient should be monitored for a long time (at least 
5 years) due to the potential for recurrence [13, 16, 18].
Conclusions
Malignant ovarian tumors in girls and adolescent is very 
rare pathology, however, if not treated, it may be poten-
tially lethal. The most frequent tumors in this particular 
age group are the tumors of germ cells – dysgermino-
mas. Symptoms are very non-specific, this is why these 
tumors are often diagnosed late. Juvenile or teenage 
girl’s complains about abdominal pain, a growth in the 
abdominal area, disruptions of menstrual cycle or signs 
of premature puberty, should rise a suspicion of ovarian 
tumor. Early diagnosis and treatment have a very good 
recovery rate [30, 31].
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